123 related articles for article (PubMed ID: 21669375)
1. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.
Félix J; Andreozzi V; Soares M; Borrego P; Gervásio H; Moreira A; Costa L; Marcelo F; Peralta F; Furtado I; Pina F; Albuquerque C; Santos A; Passos-Coelho JL;
Value Health; 2011 Jun; 14(4):499-505. PubMed ID: 21669375
[TBL] [Abstract][Full Text] [Related]
2. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
5. Canadian health care institution resource utilization resulting from skeletal-related events.
Habib MJ; Merali T; Mills A; Uon V
Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
[TBL] [Abstract][Full Text] [Related]
7. Skeletal-related events among breast and prostate cancer patients: towards new treatment initiation in Malaysia's hospital setting.
Ezat SW; Syed Junid SM; Noraziani K; Zafar A; Saperi S; Nur AM; Aizuddin AN; Ismail F; Abdullah N; Zainuddin ZM; Mohd Kassim AY; Haflah NH
Asian Pac J Cancer Prev; 2013; 14(5):3357-62. PubMed ID: 23803129
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
9. Costs of prostate cancer, metastatic to the bone, in the Netherlands.
Groot MT; Boeken Kruger CG; Pelger RC; Uyl-de Groot CA
Eur Urol; 2003 Mar; 43(3):226-32. PubMed ID: 12600424
[TBL] [Abstract][Full Text] [Related]
10. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
11. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
12. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
13. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
14. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain.
Pockett RD; Castellano D; McEwan P; Oglesby A; Barber BL; Chung K
Eur J Cancer Care (Engl); 2010 Nov; 19(6):755-60. PubMed ID: 19708928
[TBL] [Abstract][Full Text] [Related]
15. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
[TBL] [Abstract][Full Text] [Related]
16. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.
Sherman EJ; Pfister DG; Ruchlin HS; Rubin DM; Radzyner MH; Kelleher GH; Slovin SF; Kelly WK; Scher HI
Cancer; 2001 Feb; 91(4):841-53. PubMed ID: 11241254
[TBL] [Abstract][Full Text] [Related]
17. Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.
Ter Heine R; Frederix GW; Geenen JW; Hövels AM; van Vulpen M; Kooistra A; De Klerk JM; Bloemendal HJ
J Comp Eff Res; 2017 Oct; 6(7):575-581. PubMed ID: 29091013
[TBL] [Abstract][Full Text] [Related]
18. Resource use in the last 6 months of life among patients with heart failure in Canada.
Kaul P; McAlister FA; Ezekowitz JA; Bakal JA; Curtis LH; Quan H; Knudtson ML; Armstrong PW
Arch Intern Med; 2011 Feb; 171(3):211-7. PubMed ID: 20937918
[TBL] [Abstract][Full Text] [Related]
19. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland.
Delcò F; Egger R; Bauerfeind P; Beglinger C
Aliment Pharmacol Ther; 2005 Mar; 21(5):615-22. PubMed ID: 15740546
[TBL] [Abstract][Full Text] [Related]
20. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
